Skip to main content

ARS Pharmaceuticals, Inc.

corporate_fare Company Profile

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ·Life Sciences·CIK 0001671858

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is identified in the European Union and United Kingdom by the trade name EURneffy, and in China by the trade name 优敏速 (Yōumǐnsù). It is the first and only FDA and European Commission-approved needle-free epinephrine product, and also holds approvals in the U.K., Japan, Australia, and China. This product represents the first new delivery method for epinephrine in over 35 years. neffy is a proprietary composition of epinephrine combined with an innovative absorption enhancer called Intravail. This allows neffy to safely deliver epinephrine intranasally at a low dose, achieving exposures comparable to approved injectable products across various dosing conditions, including repeat dosing and allergen challenge. The company believes neffy's "no needle, no injection" approach addresses a significant unmet need, as approximately 40 million people in the U.S. experience Type I allergic reactions.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for SPRY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for SPRY spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • ARS Pharma 10-Q: Q3 Revenue $37.7M, Net Loss Narrows to $35.6M, $138.4M Cash
  • ARS Pharma Q3 Revenue $37.7M, Net Loss Narrows to $35.6M; Breakeven Target Reaffirmed
  • Q3 Revenue Climbs to $37.7M as Net Loss Narrows and SG&A Drops 42%
  • ARS Pharmaceuticals Doubles Epinephrine Market Share as neffy Revenue Climbs
  • ARS Pharmaceuticals Q2: Revenue Doubles, But Losses Widen and Legal Battles Mount

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$84.28M
Net Income
-$171.3M
Diluted EPS
-$1.74
Op. Cash Flow
-$170.87M
Free Cash Flow
-$171.21M
Operating Income
-$179.45M
Cash & Equivalents
$41.32M
Total Debt
$96.37M
Debt / Equity
0.84×
Net Margin
-203.3%
Shares Outstanding
99.29M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-097478

Short Interest & Short Volume

11.09 days to cover

FINRA reported short interest of 18,990,650 shares in SPRY as of the October 30, 2026 settlement, a 4.2% decrease from the prior period — about 11.1 days to cover at its recent average daily volume. On November 20, 2026, 67.3% of SPRY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,990,650 shares as of October 30, 2026
Change vs prior period▼ 4.2%
Days to cover11.09 at avg daily volume of 1,712,099
Daily short volume (FINRA facilities)67.3% of 1,319,491 shares on November 20, 2026
5-day average short volume59.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$2.96
52-week range · as of 2026-11-05 $2.59 – $13.15
Market cap
$297.56M
Volume
2.8M (1.2× avg)
3-mo avg 2.3M
Live data · 2026-11-22 12:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SPRY - Latest Insights

SPRY
Nov 05, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $2.96 info
Change: +$0.310 (+12%) info
Market Cap: $297.564M info
SPRY
Nov 05, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $2.96 info
Change: +$0.310 (+12%) info
Market Cap: $297.564M info
SPRY
Nov 05, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $2.96 info
Change: +$0.310 (+12%) info
Market Cap: $297.564M info
SPRY
Aug 13, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.31
Real-time Price: $2.96 info
Change: -$2.35 (-44%) info
Market Cap: $297.564M info
SPRY
Aug 13, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $2.96 info
Change: -$2.36 (-44%) info
Market Cap: $297.564M info
SPRY
Aug 13, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $2.96 info
Change: -$2.16 (-42%) info
Market Cap: $297.564M info
SPRY
Jul 17, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.03
Real-time Price: $2.96 info
Change: -$4.07 (-58%) info
Market Cap: $297.564M info
SPRY
Jul 17, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.03
Real-time Price: $2.96 info
Change: -$4.07 (-58%) info
Market Cap: $297.564M info
SPRY
Jul 07, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.83
Real-time Price: $2.96 info
Change: -$4.87 (-62%) info
Market Cap: $297.564M info
SPRY
Jun 24, 2026, 6:25 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $8.01
Real-time Price: $2.96 info
Change: -$5.05 (-63%) info
Market Cap: $297.564M info
SPRY
May 15, 2026, 6:17 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.99
Real-time Price: $2.96 info
Change: -$5.03 (-63%) info
Market Cap: $297.564M info
SPRY
May 15, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.99
Real-time Price: $2.96 info
Change: -$5.03 (-63%) info
Market Cap: $297.564M info
SPRY
May 15, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.00
Real-time Price: $2.96 info
Change: -$5.04 (-63%) info
Market Cap: $297.564M info
SPRY
May 13, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.63
Real-time Price: $2.96 info
Change: -$5.67 (-66%) info
Market Cap: $297.564M info
SPRY
May 13, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $8.65
Real-time Price: $2.96 info
Change: -$5.69 (-66%) info
Market Cap: $297.564M info
SPRY
Apr 15, 2026, 6:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.32
Real-time Price: $2.96 info
Change: -$5.36 (-64%) info
Market Cap: $297.564M info
SPRY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.51
Real-time Price: $2.96 info
Change: -$5.55 (-65%) info
Market Cap: $297.564M info
SPRY
Mar 16, 2026, 8:53 AM EDT
Source: FinanceWire
Importance Score:
8
Price at Filing: $8.44
Real-time Price: $2.96 info
Change: -$5.48 (-65%) info
Market Cap: $297.564M info
SPRY
Mar 09, 2026, 6:07 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $9.09
Real-time Price: $2.96 info
Change: -$6.13 (-67%) info
Market Cap: $297.564M info
SPRY
Mar 09, 2026, 6:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $2.96 info
Change: -$6.13 (-67%) info
Market Cap: $297.564M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets